A Phase 2 Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, parallel-dosing, multi-center study to evaluate the safety
and efficacy of rencofilstat as evidenced by assessing changes in the HepQuant Shunt Disease
Severity Index Score (DSI), safety labs, and clinical events in adult NASH subjects with
compensated Fibrosis stage F3. Antifibrotic biomarker activity will be evaluated on an
exploratory basis.